GlassScriptPhysician profile
Vinh Q Chau
NPI 1134567134
$6,769.30
in general payments reported to CMS, 2019-2025
16 companies · $732 in 2025
The $732 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,765 · 2020: $492 · 2021: $90.91 · 2022: $679 · 2023: $641 · 2024: $370 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,252.63 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novo Nordisk INC | $435.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.37 | 2020-2025 | Farxiga |
| United Therapeutics Corporation | $150.50 | 2023 | Remodulin, Tyvaso, Orenitram |
| Pfizer INC. | $135.35 | 2019 | |
| Medtronic Vascular, INC. | $120.24 | 2019 | |
| Genzyme Corporation | $99.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.63 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $44.29 | 2019 | |
| Scpharmaceuticals INC. | $41.73 | 2025 | |
| Cvrx, INC. | $27.48 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.90 | 2024-2025 | Lifevest |
| Medtronic, INC. | $15.79 | 2021 | |
| Lilly USA, LLC | $14.91 | 2025 | Zepbound, Mounjaro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.